NASDAQ:NVAX Novavax (NVAX) Stock Price, News & Analysis $7.88 -0.33 (-4.02%) Closing price 04:00 PM EasternExtended Trading$7.89 +0.01 (+0.16%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Novavax Stock (NASDAQ:NVAX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Novavax alerts:Sign Up Key Stats Today's Range$7.85▼$8.3050-Day Range$7.88▼$11.0952-Week Range$6.20▼$11.97Volume3.02 million shsAverage Volume3.78 million shsMarket Capitalization$1.30 billionP/E RatioN/ADividend YieldN/APrice Target$13.00Consensus RatingHold Company Overview Novavax, Inc. is a clinical-stage biotechnology company headquartered in Gaithersburg, Maryland, that specializes in the discovery, development and commercialization of next-generation vaccines to prevent serious infectious diseases. Founded in 1987, the company has built a platform based on recombinant nanoparticle technology and its proprietary Matrix-M™ adjuvant to enhance immune responses. The company’s lead product is NVX-CoV2373, a protein-based vaccine designed to elicit a robust immune response against the SARS-CoV-2 virus. In addition to its COVID-19 vaccine, Novavax is advancing candidates targeting respiratory syncytial virus (RSV) and seasonal influenza. These programs leverage the same nanoparticle and adjuvant technologies to address ongoing unmet needs in respiratory infectious disease. Novavax operates globally, with research and development facilities in North America and manufacturing partnerships in Europe, Asia and Africa. Collaborations with organizations such as the Serum Institute of India and SK bioscience support its ability to supply vaccines in diverse markets. This international footprint enables the company to respond rapidly to public health emergencies and to pursue broad distribution of its products. Under the leadership of President and Chief Executive Officer John C. Jacobs, who joined the company in 2021, Novavax has focused on scaling manufacturing capacity and securing regulatory approvals for its vaccine candidates. The company’s executive team and board include experienced professionals from the vaccine and biopharmaceutical industries, guiding its efforts to expand the global reach of its proprietary vaccine platform.AI Generated. May Contain Errors. Read More Novavax Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks43rd Percentile Overall ScoreNVAX MarketRank™: Novavax scored higher than 43% of companies evaluated by MarketBeat, and ranked 581st out of 840 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingHold Consensus RatingNovavax has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 1 strong buy rating, 5 buy ratings, 1 hold rating, and 3 sell ratings.Upside PotentialNovavax has a consensus price target of $13.00, representing about 65.0% upside from its current price of $7.88.Amount of Analyst CoverageNovavax has only been the subject of 4 research reports in the past 90 days.Read more about Novavax's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Novavax are expected to decrease in the coming year, from ($0.19) to ($0.25) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Novavax is -13.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Novavax is -13.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Novavax's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted28.31% of the float of Novavax has been sold short.Short Interest Ratio / Days to CoverNovavax has a short interest ratio ("days to cover") of 9.28.Change versus previous monthShort interest in Novavax has recently increased by 1.54%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNovavax does not currently pay a dividend.Dividend GrowthNovavax does not have a long track record of dividend growth. News and Social Media2.8 / 5News Sentiment0.41 News SentimentNovavax has a news sentiment score of 0.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.67 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Novavax this week, compared to 8 articles on an average week.Search Interest17 people have searched for NVAX on MarketBeat in the last 30 days. This is an increase of 70% compared to the previous 30 days.MarketBeat Follows5 people have added Novavax to their MarketBeat watchlist in the last 30 days. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Novavax insiders have not sold or bought any company stock.Percentage Held by Insiders1.60% of the stock of Novavax is held by insiders.Percentage Held by Institutions53.04% of the stock of Novavax is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Novavax's insider trading history. Receive NVAX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Novavax and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NVAX Stock News HeadlinesNovavax (NVAX) Registers a Bigger Fall Than the Market: Important Facts to Note2 hours ago | finance.yahoo.com3 Small-Cap Stocks Walking a Fine LineJuly 20 at 9:08 AM | finance.yahoo.comYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.July 20 at 1:00 AM | Profits Run (Ad)HRMY Posts Preliminary Q2 Revenues, Announces CFO TransitionJuly 17 at 6:58 PM | finance.yahoo.comNovavax (NVAX) Stock Sinks As Market Gains: Here's WhyJuly 14, 2026 | finance.yahoo.comAGEN Stock Jumps on Securing $340M Financing to Fund Strategic PivotJuly 14, 2026 | finance.yahoo.com1 Cash-Heavy Stock on Our Buy List and 2 That UnderwhelmJuly 14, 2026 | finance.yahoo.comFBRX Stock Rallies 78% on Positive Early-Stage Vitiligo Study DataJuly 10, 2026 | finance.yahoo.comSee More Headlines NVAX Stock Analysis - Frequently Asked Questions How have NVAX shares performed this year? Novavax's stock was trading at $6.72 on January 1st, 2026. Since then, NVAX stock has increased by 17.3% and is now trading at $7.88. How were Novavax's earnings last quarter? Novavax, Inc. (NASDAQ:NVAX) announced its quarterly earnings data on Wednesday, May, 6th. The biopharmaceutical company reported ($0.06) EPS for the quarter, topping analysts' consensus estimates of ($0.25) by $0.19. The firm's revenue was down 79.0% on a year-over-year basis. Read the conference call transcript. When did Novavax's stock split? Novavax shares reverse split on the morning of Friday, May 10th 2019.The 1-20 reverse split was announced on Wednesday, May 8th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 9th 2019. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of Novavax? Shares of NVAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Novavax own? Based on aggregate information from My MarketBeat watchlists, some other companies that Novavax investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Moderna (MRNA), Advanced Micro Devices (AMD), Pfizer (PFE) and Alibaba Group (BABA). Company Calendar Last Earnings5/06/2026Today7/20/2026Next Earnings (Estimated)8/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (4m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 NVAX's financial health is in the Green zone, according to TradeSmith. NVAX has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryBiotechnology Current SymbolNASDAQ:NVAX CIK1000694 Webwww.novavax.com Phone(240) 268-2000Fax240-268-2100Employees1,990Year Founded1987Price Target and Rating Average Price Target for Novavax$13.00 High Price Target$19.00 Low Price Target$6.00 Potential Upside/Downside+65.0%Consensus RatingHold Rating Score (0-4)2.40 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)($0.58) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$440.30 million Net Margins-14.73% Pretax Margin-14.45% Return on Equity-14.82% Return on Assets1.23% Debt Debt-to-Equity RatioN/A Current Ratio2.48 Quick Ratio2.45 Sales & Book Value Annual Sales$1.12 billion Price / Sales1.15 Cash Flow$3.37 per share Price / Cash Flow2.34 Book Value($0.79) per share Price / Book-9.97Miscellaneous Outstanding Shares164,440,000Free Float161,807,000Market Cap$1.30 billion OptionableOptionable Beta2.43 Social Links 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:NVAX) was last updated on 7/20/2026 by MarketBeat.com Staff. From Our PartnersBacked Company Could Save Power GridA small Colorado company holds the rights to technology that could protect the U.S. public power grid from col...Altimetry | SponsoredBlackRock is hoarding it. JPMorgan is hoarding it. Do you own it?BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredNVIDIA offered $40B. The answer was no.Apple, NVIDIA, Google, Amazon, and Samsung all pay one company billions in royalties every year. NVIDIA tried ...Behind the Markets | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredI found Rolls-Royce at $2 - now I see the same setup againIn 2022, Karim Rahemtulla recommended Rolls-Royce under $2 - a misunderstood aerospace name the market had wri...Monument Traders Alliance | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredYour withdrawal order could cost you in taxesIf you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answe...SmartAsset | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Novavax, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Novavax With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
